Glucotrack (NASDAQ:GCTK) on Tuesday reported the successful completion of its first in human clinical study, sending shares up ~60% in the morning trade. This study represents first real-time ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technologyRUTHERFORD, N.J., Feb. 26, 2025 (GLOBE ...

(RTTNews) - Glucotrack, Inc. (GCTK), a medical technology company focused on innovative diabetes solutions, on Tuesday announced the successful completion of its first in-human clinical study for ...

Glucotrack, Inc. GCTK reports it has achieved a significant milestone in its mission to transform diabetes management through three distinct advances: direct blood glucose measurement, hassle-free ...

Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...

RUTHERFORD, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the ...

Glucotrack (GCTK) announced that Ted Williams has been named Vice President of Regulatory Affairs, effective immediately. He served as Vice President, Regulatory Affairs/Quality Assurance for ...